This content is from: Premium

An Unlikely Cure

Abandoned by venture capitalists and investment bankers, biotech companies are turning to hedge funds for the capital and advice they need to get their drugs to market.

In 2004, Andrew Baum, the CEO of SemBioSys Genetics, had a problem. The small Calgary-based biotechnology firm was running out of cash, and the venture capitalists that had funded it a decade earlier were growing impatient. The solution: Take his company public. Baum, an experienced entrepreneur who had sold biotech

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content